FDA Approves Personalized Cellular Therapy for Advanced Leukemia
Landmark decision for the field of cancer immunotherapy for first therapy based on gene transfer approved by the FDA.
Read moreDr. Bruce Levine Appointed as Deputy Director of Technology Innovation at CCI
New role to coordinate the assessment and integration of new technologies into the continuum of new cellular therapies at the Center for Cellular Immunotherapies (CCI).
Read morePilot Study Tests CAR T-Cell Immunotherapy in Glioblastomas
Science Translational Medicine reports results of phase 1 safety study of autologous CAR T cells targeted to EGFR variant III in glioblastoma patients.
Read moreFDA Approval Recommendation for CAR T-Cell Therapy
FDA advisory committee unanimously approves first personalized cellular therapy developed at Penn for pediatric and young adult leukemia.
Read moreTumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
A new Penn Medicine preclinical study in Cell, "Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade," suggests that an existing drug known as a JAK in
Read moreReengineering Chimeric Antigen Receptor T Cells for Targeted Therapy of Autoimmune Disease
In a Science study with potentially major implications for the future treatment of autoimmunity and related conditions, co-senior author
Read more
